AVXL Anavex Life Sciences Corp.
USHealthcareAs of 2026-07-10 16:00
Why AVXL matters now
Anavex Life Sciences Corp. (AVXL) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.50 with -7.41% on the session and $231.7M in market capitalization; recent performance reads 1-month +2.25% and YTD -23.31%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-5.7M, and EPS of $-0.06. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -13.5%.
The latest indexable market news headline is "Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $11.00; recent insider activity includes Kellmeyer Terrie filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.92
P/S
0.00
EV/EBITDA
-3.12
DCF Value
$1.17
FCF Yield
-13.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-38.8%
ROA
-30.0%
ROIC
-35.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-5.7M | $-0.06 |
| Q4 2025 | $0.00 | $-9.8M | $-0.11 |
| FY 2025 | $0.00 | $-46.4M | $-0.54 |
| Q3 2025 | $0.00 | $-13.2M | $-0.16 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$11.00
Target (Median)
$11.00
Target Range
$11.00 - $11.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.12
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.